Atypical antipsychotic drugs and long-term outcome in schizophrenia

Journal of Clinical Psychiatry

Volumn 57, Issue SUPPL. 11, 1996, Pages 53-60

  Weiden, Peter ^a   Aquila, Ralph ^a   Standard, Janet ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE;

DRUG EFFICACY; DRUG RESPONSE; HUMAN; PARKINSONISM; PATIENT COMPLIANCE; PRIORITY JOURNAL; RELAPSE; REVIEW; SCHIZOPHRENIA; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLINICAL TRIALS; CLOZAPINE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PIRENZEPINE; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; RECURRENCE; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 0029985119     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Drake R, Gates C, Whitaker A, et al. Suicide among schizophrenics: a review. Compr Psychiatry 1985;26:90-100
2. Weiden P, Olfson M. The cost of relapse in schizophrenia. Schizophr Bull 1995;21:419-428
3. Eaton WW, Thara R, Federman B, et al. Structure and course of positive and negative symptoms in schizophrenia. Arch Gen Psychiatry 1995;52: 127-133
4. Lehman A, Ward N, Linn L. Chronic mental patients: the quality of life issue. Am J Psychiatry 1982;139:1271-1276
5. Lehman A. Vocational rehabilitation in schizophrenia. Schizophr Bull 1995;21:645-656
6. Ryan F. The Forgotten Plague: How the Battle Against Tuberculosis Was Won - and Lost. Boston, Mass: Little, Brown and Company; 1992
7. Essock S. Clozapine's effectiveness: results of a 2-year randomized trial. Presented at the New Clinical Drug Evaluation Unit; 1996; Boca Raton, Fla
8. Essock S, Hargreaves WA, Dohm FA, et al. Clozapine eligibility among state hospital patients. Schizophr Bull 1996;22:15-25
9. Satterlee W, Dellce M, Beasley C, et al. Effectiveness of olanzapine in long-term continuation treatment. Presented at the New Clinical Drug Evaluation Unit; June 2, 1996; Boca Raton, Fla
10. Addington DE, Jones B, Bloom D, et al. Reduction in hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clinical Therapeutics 1993;15:917-925
11. Albright P, Livingstone S, Keegan D, et al. Health-care resource utilization and costs before and after initiation of risperidone treatment in patients with schizophrenia. Clinical Drug Investigation 1996;11:289-299
12. Schooler NR, Levine J. Strategies for enhancing drug therapy of schizophrenia. Am J Psychother 1983;37:521-532
13. Marder SR, Van PuttenT, Mintz J, et al. Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Arch Gen Psychiatry 1987;44:518-521
14. Kane JM, Rifkin A, Woerner M, et al. Low-dose neuroleptic treatment of outpatient schizophrenics. Arch Gen Psychiatry 1983;40:893-896
15. Borison R. Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics. Janssen Clinical Psychiatry 1995;15(suppl 1):24-29
16. Hale A. Will the new anti-psychotics improve the treatment of schizophrenia? BMJ 1993;307:749-750
17. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel group study versus haloperidol. Br J Psychiatry 1995;166:712-726
18. Huttunen M. The evolution of the serotonin-dopamine antagonist concept. J Clin Psychiatry 1995;15(suppl 1):4-10
19. Moore N, Rees G, Sanger G, et al. Effects of olanzapine and other antipsychotic agents on responding maintained by a conflict schedule. Behavioural Pharmacology 1994;5:196-202
20. Moore N, Tupper D, Hotten T. Olanzapine. Drugs of the Future 1994;19(2): 114-117
21. Bymaster F, Calligaro D, Falcone J, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996; 14:87-96
22. Bymaster F, Hemrick-Luecke S, Perry K, et al. Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology 1996;124: 87-94
23. Kinon B, Lieberman J. Mechanism of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology 1996;124:2-34
24. Ring B, Binkley S, Vanderbranden M, et al. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6, and CYP3A. British Journal of Clinical Pharmacology 1996;41:181-186
25. Ring B, Callow J, Lindsay T, et al. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. Journal of Pharmacology and Experimental Therapeutics 1996;276(2):658-666
26. Beasley C, Sanger T, Satterlee W, et al. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 1996;124:159-167
27. Beasley C, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double blind olanzapine trial. Neuropsychopharmacology 1996;14:111-123
28. Casey DE. Side effect profiles of new antipsychotic agents. J Clin Psychiatry 1996;57(suppl 11):40-45
29. Street J, Tamura R, Sanger T, et al. A comparison of the incidence of treatment-emergent dyskinetic symptoms in patients treated with olanzapine and haloperidol. Presented at the New Clinical Drug Evaluation Unit; 1996; Boca Raton, Fla
30. Hamilton S, Genduso L, Beasley C. Quality of life outcomes for olanzapine and haloperidol treatment for schizophrenia and related psychotic disorders. Presented at the New Clinical Drug Evaluation Unit; 1996; Boca Raton, Fla
31. Breier A, Buchanan RW, Kirkpatrick B, et al. Clozapine treatment in schizophrenic outpatients: preliminary results from a double-blind efficacy study. Schizophr Res 1991;4:315-320
32. Breier A, Buchanan RW, Irish D, et al. Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns. Hosp Community Psychiatry 1993;44:1145-1149
33. Sacks O. Awakenings. New York, NY: HarperCollins, 1990
34. Kopelowicz A. And when they awaken what will they find? Journal of the California Alliance for the Mentally Ill 1996;7(2):15-16
35. Larsen P, Ashleigh E. Response to risperidone: a two edged sword? Journal of the California Alliance for the Mentally Ill 1996;7(2):17-18
36. Moller M. Learning from the awakenings. Journal of the California Alliance for the Mentally Ill 1996;7(2):10-11